Pieris Pharmaceuticals, Inc.  Banner Image

Pieris Pharmaceuticals, Inc.

  • Ticker PIRS
    Exchange NASDAQ More
  • Industry Biotechnology More
  • Sector Healthcare More
Pieris Pharmaceuticals, Inc.  Logo Image
  • 51-200 Employees
  • Based in Boston, Massachusetts
Pieris is a clinical-stage biotechnology company that discovers and develops Anticalin protein-based drugs to target validated disease pathways in a unique and transformative way. Our pipeline includes inhalable Anticalin proteins to treat respiratory diseases, immuno-oncology multi-specifics tailored for the tumor microenvironment, and a half-life-optimized Anticalin protein to treat anemiaMore. Proprietary to Pieris, Anticalin proteins are a novel class of therapeutics validated in the clinic and by partnerships with leading pharmaceutical companies. Anticalin® is a registered trademark of Pieris.
4.8 / 5.0 (194)

Pieris Pharmaceuticals, Inc. reports have an aggregate usefulness score of 4.8 based on 194 reviews.

Pieris Pharmaceuticals, Inc.

Most Recent Annual Report

Pieris Pharmaceuticals, Inc.
MOST RECENT 2022 Annual Report and Form 10K

Older/Archived Annual Reports

Pieris Pharmaceuticals, Inc.  Logo Image

Rate This Report

Your vote helps our reports be more useful
Rating Saved!

Thank you for your feedback!